A5084830142- Photodynamic Therapy Research Studies
- Nanoplatforms for cancer theranostics
- Nonmelanoma Skin Cancer Studies
- Skin Protection and Aging
- Wound Healing and Treatments
- Porphyrin and Phthalocyanine Chemistry
- Proteoglycans and glycosaminoglycans research
- Photoacoustic and Ultrasonic Imaging
- Cancer Research and Treatments
- Skin and Cellular Biology Research
- Heat shock proteins research
- Retinoids in leukemia and cellular processes
- Porphyrin Metabolism and Disorders
- Ocular Oncology and Treatments
- Cutaneous lymphoproliferative disorders research
- Cutaneous Melanoma Detection and Management
- bioluminescence and chemiluminescence research
- Infectious Diseases and Mycology
- Nail Diseases and Treatments
- Autoimmune Bullous Skin Diseases
- Cancer, Hypoxia, and Metabolism
- Polysaccharides and Plant Cell Walls
- Cell Adhesion Molecules Research
- Click Chemistry and Applications
- Photosynthetic Processes and Mechanisms
Cleveland Clinic
2016-2025
Cleveland Clinic Lerner College of Medicine
2016-2025
Dallas Plastic Surgery Institute
2019-2024
Massachusetts General Hospital
2014-2024
Case Western Reserve University
2009-2024
Cleveland State University
2013-2022
Clinical Research Consortium
2022
Cerner (United States)
2019-2020
Harvard University
1999-2019
Sun Chemical (United States)
2019
Improved treatment outcomes for non-melanoma skin cancers can be achieved if Vitamin D (Vit D) is used as a neoadjuvant prior to photodynamic therapy (PDT). However, the mechanisms this effect are unclear. Vit elevates protoporphyrin (PpIX) levels within tumor cells, but also exerts immune-modulatory effects. Here, two murine models, UVB-induced actinic keratoses (AK) and human squamous cell carcinoma (A431) xenografts, were analyze time course of local systemic immune responses after PDT ±...
Abstract Purpose: To improve treatment efficacy and tumor cell selectivity of δ-aminolevulinic acid (ALA)-based photodynamic therapy (PDT) via pretreatment cells tumors with methotrexate to enhance intracellular photosensitizer levels. Experimental Design: Skin carcinoma cells, in vitro vivo, served as the model system. Cultured human SCC13 HEK1 normal keratinocytes, vivo skin models were preconditioned for 72 h then incubated ALA 4 h. Changes protoporphyrin IX (PpIX) levels survival after...
Photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) to drive production of an intracellular photosensitiser, protoporphyrin IX (PpIX), is a promising cancer treatment. However, ALA-PDT still suboptimal for thick or refractory tumours. Searching new approaches, we tested known inducer cellular differentiation, methotrexate (MTX), in combination with LNCaP cells. Methotrexate alone promoted growth arrest, and apoptosis. pretreatment (1 mg l−1, 72 h) followed by ALA (0.3 mM, 4...
Abstract Photodynamic therapy, mediated by exogenously administered aminolevulinic acid (ALA-PDT), followed exposure to a laser or broadband light source, is promising modality for treatment of many types cancers; however, it remains inadequate treat large, deep, solid tumors. In this article, we report that calcitriol, the active form vitamin D3, can be before ALA as nontoxic preconditioning regimen markedly increase efficacy ALA-PDT. Using mouse models squamous cell skin cancer preclinical...
Photodynamic therapy (PDT) is a treatment modality that uses specific photosensitizing agent, molecular oxygen, and light of particular wavelength to kill cells targeted by the therapy. Topically administered aminolevulinic acid (ALA) widely used effectively treat cancerous precancerous skin lesions, resulting in tissue damage little no scarring. The targeting aspect arises from fact ALA preferentially converted into protoporphyrin IX (PpIX) neoplastic cells. To monitor amount PpIX tissues,...
Dosimetry for aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy of actinic keratosis was examined with an optimized fluorescence dosimeter to measure PpIX during treatment. While insufficient generation may be indicator incomplete response, there exists no standardized method quantitate production at depths in the skin clinical treatments. In this study, a spectrometer-based point probe system used sample from superficial (blue wavelength excitation) and deeper...
Abstract Photodynamic therapy (PDT), using 5-aminolevulinic acid (ALA) to drive synthesis of protoporphryin IX (PpIX) is a promising, scar-free alternative surgery for skin cancers, including squamous cell carcinoma (SCC) and SCC precursors called actinic keratoses. In the United States, PDT only FDA approved treatment keratoses; this narrow range indications could be broadened if efficacy were improved. Toward that goal, we developed mechanism-based combination approach 5-fluorouracil...
Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis squamous cell carcinoma, yet large response variations effect are common between individuals. The aim this study was to compare pre-treatment strategies that increase the therapeutic effect, including fractionated light delivery during PDT (fPDT) use iron chelator desferrioxamine (DFO), separately combined.Optical measurements...
Patients with cancer often confront the decision of whether to continue high-dose chemotherapy at expense cumulative toxicities. Reducing dose regimens while preserving efficacy is sorely needed preserve performance status these vulnerable patients, yet has not been prioritized. Here, we introduce a dual pronged approach modulate microenvironment desmoplastic pancreatic tumors and enable significant deescalation FDA-approved chemotherapeutic nanoliposomal irinotecan (nal-IRI) without...
ABSTRACT Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) can be effective for select basal cell carcinoma (BCC) lesions. However, the histological depth and subtype of tumors that respond to PDT remain uncertain. Here, we report a clinical trial high-dose oral Vitamin D (VD), used as neoadjuvant BCC. In this multi-institutional, intra-patient, randomized trial, 35 patients (9 Gorlin Syndrome) received three sessions (20% ALA; 417 nm blue light) preceded by VD, placebo, or...